All In MedTech

Company

Lifescan

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

From SEC filings.

We found no SEC financing filings under the name Lifescan, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

No 5%+ shareholder filings or SBIR grants found under the name Lifescan.

Latest FDA decisions

Search the Clearance Tracker

1 more FDA decisions with a free account

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT06052371 · 99 participants · Start Oct 16, 2023 · Primary completion Dec 1, 2023

    Device: VerioVue (Enhancements) blood glucose monitoring system · For: Diabetes Mellitus

    Sites: London, United Kingdom; Manchester, United Kingdom · 3 sites in all

  • NCT06121856 · 116 participants · Start Feb 7, 2023 · Primary completion Apr 28, 2023

    Device: VerioVue Enhancements BGMS · For: Diabetes Mellitus

    Sites: Edinburgh, United Kingdom

  • NCT05354297 · 800 participants (planned) · Start Jul 26, 2022 · Primary completion Apr 1, 2023

    Device: Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app; Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app and 2 more · For: Diabetes Mellitus, Type 2

    Sites: San Mateo, California

13 more trials with a free account

Reports received

65

Received Nov 1, 2025 to Nov 20, 2026

Malfunction reports

2

3.1% of reports

Injury reports

62

95% of reports

Death reports

1

1.5% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 2343600
Jan 2432200
Feb 2403100
Mar 2401000
Apr 2401600
May 2421100
Jun 2401700
Jul 2401200
Aug 2401400
Sep 2421200
Oct 2411500
Nov 2411200
Dec 240600
Jan 2501000
Feb 250800
Mar 2501000
Apr 2501000
May 252000
Jun 250800
Jul 252800
Aug 251600
Sep 250600
Oct 250800
Nov 250600
Dec 250000
Jan 261200
Feb 260000
Mar 2601200
Apr 261610
May 260400
Jun 260800
Jul 2601100
Aug 260300
Sep 260800
Oct 260200
Nov 260000

Device types named most often

Last 12 months, by FDA product code. A company that sells more gets more reports.

Brand names named most often

Last 12 months, as written on the reports. One product can appear under several spellings.

7 more in this ranking with a free account

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

24 more recall records with a free account

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.